Skip to content

Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL)

Expanded Access to Antiretroviral Therapy in Africa: Assessment of the Patients' Management in District Hospitals With a Simplified Follow-up Approach (ANRS 12110 STRATALL)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00301561
Enrollment
459
Registered
2006-03-13
Start date
2006-05-31
Completion date
2010-10-31
Last updated
2016-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS, HIV Infections

Keywords

Antiretroviral treatment, Expanded access, Africa, Treatment Naive

Brief summary

Access to antiretroviral therapy (ART) is still limited in Africa (11% of patients in immediate need in June 2005). Face to the scope of the need and the constraints (unavailability and cost of viral load and CD4 cell count, lack of physicians…), WHO has developed a follow-up approach based on a simplified monitoring. However, this simplified approach which represents a major stake for the expanded access to ART has been little evaluated against the gold standard approach.

Detailed description

Justification Access to antiretroviral therapy (ART) is still limited in Africa (11% of patients in immediate need in June 2005). Face to the scope of the need and the constraints (unavailability and cost of viral load and CD4 cell count, lack of physicians…), WHO has developed a follow-up approach based on a simplified monitoring. This simplified approach restricting the use of complementary exams including biologic criteria of effectiveness and tolerability, some people consider this approach as dangerous for the patient but also for the community (rapid emergence of resistances) and that it would be preferable to treat less patients and only with the gold standard approach. In practice, this simplified approach which represents a major stake for the expanded access to ART has been little evaluated against the gold standard approach. Objectives Main objective: To compare the increase in the CD4 cell count in patients receiving ART with a simplified approach and in those treated with the gold standard approach in district hospitals. Secondary objectives: To compare between the two approaches the virologic effectiveness, survival, treatment interruptions, number of patients lost to follow-up, clinical progression, clinical and biologic tolerability, adherence, emergence of drug resistances, impact on patients' daily life, acceptability by the patients and health professionals, and cost-effectiveness performances. Methods Randomised, controlled, multicentre, non inferiority, intervention trial, without blind for approach, in 9 district hospitals of the Province du Centre in Cameroon. 430 adult patients will be randomised in two groups (simplified approach or gold standard approach) with a 1:1 ratio and followed for 24 months. In the simplified approach, the results of the HIV-1 viral load and CD4 cell count will not be available for the management of patients, the biologic assessment of tolerability will be limited and some clinical consultations will be performed by nurses under the physicians' responsibility; the remainder will be similar to the gold standard approach. Planning The study will start in the first semester of 2006. The full length of the study would be 36 months maximum (12 months for enrolment and 24 months for follow-up). Expected results Advices for increasing access to ART in Africa.

Interventions

PROCEDURESimplified follow-up approach of ARV treatment

Simplify treatment follow-up : * some clinical consultations will be performed by nurses under the physicians' responsibility ; * the CD4 cell count and HIV-1 viral load will not be available for the management of patients ; * the biologic assessment for tolerability will be limited

PROCEDUREStandard follow-up approach of ARV treatment

Standard treatment follow-up : * all clinical consultations will be performed by physicians ; * the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ; * the biologic assessment for tolerability will be available as needed

Sponsors

French National Agency for Research on AIDS and Viral Hepatitis
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men or women aged at least 18 years * Living in the health district of the hospital attended * Confirmed HIV-1 group M infection * Meeting one of the following criteria: * Stage III or IV (WHO classification) * Stage II (WHO classification) and total lymphocytes count ≤ 1200/mm3 * Patient agreeing on monthly follow-up and treatment for 24 months * Signed informed consent

Exclusion criteria

* HIV-1 group O or N, or HIV-2 infection * HIV-1 primary infection * Progressive tuberculosis in treatment and total lymphocytes count \> 1200/mm3 * Progressive tumor or malignant lymphoma (except cutaneous or mucous Kaposi sarcoma) * Progressive psychiatric disorder * Hepatocellular disorder * History of antiretroviral therapy * Pregnancy

Design outcomes

Primary

MeasureTime frame
Increase in the CD4 cell count measured with a FACSCount apparatus after 24 months of antiretroviral therapy24 months

Secondary

MeasureTime frame
Incidence of side effectsThrough out the trial
Incidence of clinical events (WHO stage III or IV)Through out the trial
Percentage of adherence12 and 24 months
Percentage of patients with drug resistance12 and 24 months
Acceptability by the patients and health professionals of both approaches12 and 24 months
Probability of patients lost to follow-upThrough out the trial
Cost-effectiveness ratio24 months
Percentage of patients with viral load below 400 copies/ml and 50 copies/ml, respectively (Abbott RealTime HIV-1)12 and 24 months
Survival probabilityThrough out the trial
Probability of treatment interruptionThrough out the trial
Impact on patients' daily lifeThrough out the trial

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026